Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:7474 |
Name | malignant pleural mesothelioma |
Definition | A pleural cancer that has_material_basis_in mesothelium cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer pleural cancer malignant pleural mesothelioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | GDC-0980 | malignant pleural mesothelioma | not applicable | detail... |
PIK3CA R88Q | GDC-0980 | malignant pleural mesothelioma | sensitive | detail... |
Unknown unknown | Trabectedin | malignant pleural mesothelioma | not applicable | detail... |
Unknown unknown | Cisplatin + Trabectedin | malignant pleural mesothelioma | not applicable | detail... |
Unknown unknown | Obatoclax + Trabectedin | malignant pleural mesothelioma | not applicable | detail... |
Unknown unknown | Trabectedin + Venetoclax | malignant pleural mesothelioma | not applicable | detail... |
Unknown unknown | Seprehvir | malignant pleural mesothelioma | not applicable | detail... |
Unknown unknown | AZD4547 | malignant pleural mesothelioma | no benefit | detail... |
ALK rearrange | CT-707 | malignant pleural mesothelioma | no benefit | detail... |
Unknown unknown | Cisplatin + Ganetespib + Pemetrexed Disodium | malignant pleural mesothelioma | not applicable | detail... |
Unknown unknown | Carboplatin + Ganetespib + Pemetrexed Disodium | malignant pleural mesothelioma | not applicable | detail... |
Unknown unknown | ATA2271 | malignant pleural mesothelioma | not applicable | detail... |
Unknown unknown | Cisplatin + GSK3052230 + Pemetrexed Disodium | malignant pleural mesothelioma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00996385 | Phase II | Bortezomib + Oxaliplatin | Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma | Unknown status | USA | 0 |
NCT01064648 | Phase Ib/II | Cediranib + Cisplatin + Pemetrexed Disodium | Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma | Active, not recruiting | USA | 0 |
NCT01265433 | Phase II | Montanide ISA 51 + Sargramostim Montanide ISA 51 + Sargramostim + WT1 vaccine | WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | Completed | USA | 0 |
NCT01769547 | Phase II | Dovitinib | A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy | Terminated | CAN | 0 |
NCT01868022 | Phase I | Docetaxel Cisplatin + Pemetrexed Disodium GSK3052230 Carboplatin + Paclitaxel | Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | Completed | USA | 6 |
NCT01870609 | Phase II | Defactinib | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | Terminated | USA | CAN | 13 |
NCT01907100 | Phase III | Cisplatin + Pemetrexed Disodium Nintedanib | Nintedanib (BIBF 1120) in Mesothelioma | Terminated | USA | CAN | 25 |
NCT02004028 | Phase II | Defactinib | Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma. | Terminated | USA | 0 |
NCT02399371 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Malignant Mesothelioma | Active, not recruiting | USA | 0 |
NCT02414269 | Phase I | Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | Recruiting | USA | 0 |
NCT02568449 | Phase II | Nintedanib | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | Unknown status | USA | 0 |
NCT02592551 | Phase II | Durvalumab + Tremelimumab Durvalumab | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | Active, not recruiting | USA | 0 |
NCT02639091 | Phase I | Anetumab ravtansine + Cisplatin + Pemetrexed Disodium | Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors | Completed | USA | 1 |
NCT02707666 | Phase I | Pembrolizumab Cisplatin + Pemetrexed Disodium | A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma | Recruiting | USA | 0 |
NCT02709512 | Phase II | Cisplatin + Pemetrexed Disodium ADI-PEG 20 + Cisplatin + Pemetrexed Disodium | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC) | Recruiting | USA | 4 |
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Recruiting | USA | CAN | 6 |
NCT02784171 | Phase II | Cisplatin + Pemetrexed Disodium Pembrolizumab | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma | Active, not recruiting | CAN | 2 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | 5 |
NCT02899195 | Phase II | Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505) | Active, not recruiting | USA | 0 |
NCT02899299 | Phase III | Carboplatin + Cisplatin + Pemetrexed Disodium Ipilimumab + Nivolumab | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743) | Active, not recruiting | USA | 20 |
NCT02959463 | Phase I | Pembrolizumab | Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma | Recruiting | USA | 0 |
NCT03023319 | Phase I | Bosutinib + Pemetrexed Disodium | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03075527 | Phase II | Durvalumab + Tremelimumab | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | Suspended | USA | 0 |
NCT03126630 | Phase Ib/II | Pembrolizumab Anetumab ravtansine + Pembrolizumab | Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | Recruiting | USA | CAN | 0 |
NCT03175172 | Phase II | CRS-207 + Pembrolizumab | Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM | Terminated | USA | 0 |
NCT03228537 | Phase I | Atezolizumab + Cisplatin + Pemetrexed Disodium | Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma | Active, not recruiting | USA | 0 |
NCT03319537 | Phase Ib/II | MLN4924 Cisplatin + MLN4924 + Pemetrexed Disodium | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | Recruiting | USA | 0 |
NCT03399552 | Phase Ib/II | Avelumab | Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma | Active, not recruiting | USA | 0 |
NCT03644550 | Phase II | LMB-100 + Pembrolizumab | Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | Completed | USA | 0 |
NCT03710876 | Phase III | Celecoxib + Gemcitabine Celecoxib + Gemcitabine + rAd-IFN | Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE) | Recruiting | USA | CAN | 7 |
NCT03715933 | Phase I | INBRX-109 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Recruiting | USA | 0 |
NCT03717415 | Phase Ib/II | Carboplatin + Rebastinib | A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT03760575 | Phase I | Cisplatin + Pembrolizumab + Pemetrexed Disodium | Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) | Not yet recruiting | USA | 0 |
NCT03918252 | Phase II | Ipilimumab + Nivolumab Nivolumab | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | Recruiting | USA | 0 |
NCT03920839 | Phase I | Carboplatin + Paclitaxel + Retifanlimab Cisplatin + Gemcitabine + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium + Retifanlimab | INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | Withdrawn | 0 | |
NCT04013334 | Phase II | MTG201 + Nivolumab | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | Recruiting | USA | 0 |
NCT04040231 | Phase I | Galinpepimut-S + Nivolumab + Sargramostim | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | Recruiting | USA | 0 |
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Recruiting | USA | 4 |
NCT04162015 | Phase I | Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium | A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | Recruiting | USA | 0 |
NCT04201145 | Phase I | Pembrolizumab Defactinib + Pembrolizumab | Pembrolizumab + Defactinib In Pleural Mesothelioma | Withdrawn | USA | 0 |
NCT04334759 | Phase III | Durvalumab Cisplatin + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R) | Recruiting | USA | 1 |
NCT04525859 | Phase I | Poly ICLC | Poly-ICLC (Hiltonol) Vaccine In Malignant Pleural Mesothelioma | Recruiting | USA | 0 |